Ley Orgánica de Salud (G.O. 36.579) and Venezuela Device Regulation
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Venezuelan Organic Health Law (Ley Orgánica de Salud, Gaceta Oficial N° 36.579, November 11, 1998) is the legal foundation of medical device oversight, but it is not an operating manual. What the law establishes is the organizational principle of the national health system and the power of the state to regulate health products. The concrete registration conditions, the document list, the deadlines and the fees do not appear in the statutory text at all; they are supplied by subordinate instruments and by SACS circulars.
The practical consequence is direct: a company that cites the Organic Health Law when it meets a specific problem will usually get no actionable answer, because the answer lives one or two levels below. Identifying the correct subordinate instrument is the real work. Understanding this hierarchy is the precondition for not wasting time on legal research that cannot resolve the question that prompted it.
There is a second consequence that matters for planning. Because the statute is stable and the subordinate layer is not, a compliance file that records only the law will look permanently current while being permanently out of date. The usable unit of regulatory knowledge in Venezuela is the individual instrument with its number, its publication date and its status, and the statute is only the first entry in that ledger.
2. Legal basis
| Instrument | Reference number | Publication date | Article / key point |
|---|---|---|---|
| Ley Orgánica de Salud (Organic Health Law) | Gaceta Oficial N° 36.579 | November 11, 1998 | Basic framework of the organic health law |
| Ley de Medicamentos (Medicines Law) | Gaceta Oficial N° 37.006 | August 3, 2000 | Article 18 and Article 67 |
| Reglamento Orgánico del MPPS | Gaceta Oficial N° 38.591 | December 26, 2006 | Organizational regulation of the Ministry of Health |
| Circular N° DGSACS/0002/2025 | DGSACS/0002/2025 | October 28, 2025 | Executing rules at platform and procedure level |
3. Expert insights
Insight 1: nearly 28 years separate the 1998 statute from 2026 practice, and that gap is filled by interpretation. The law has not been amended as a whole since publication, while the regulatory environment has changed fundamentally: institutions have been reorganized, the customs tariff has been replaced, and procedures have migrated to a new platform, all through subordinate instruments. Stability of the statutory text coexists with high-frequency change in the executing rules, so a company cannot infer that the requirements are unchanged from the fact that the law is unchanged.
Insight 2: the real function of the Organic Health Law is to legitimize authority, not to prescribe technical requirements. When a company needs to contest a SACS requirement or apply for an exemption, the principled provisions at statutory level are the argumentative basis, because they define what the administration is entitled to require and on what grounds. Day-to-day filing, by contrast, depends entirely on the subordinate instruments. Mixing the two registers produces either an argument that is technically correct but useless in a filing, or a filing that cannot be defended when it is challenged.
Insight 3: the intermediate layer that would normally hold sector-specific rules is missing. Unlike the RDC system of ANVISA in Brazil or the NOM system in Mexico, Venezuela has no systematic body of dedicated technical standards for medical devices. The consequence is that the circular (Circular) effectively carries the weight of a first-order executing instrument: it is the document that a reviewer opens when deciding whether a file is complete. This structural feature is examined in Article 10.
The missing middle layer has a second effect that is easy to underestimate. In systems with a technical regulation layer, a change in requirements is announced through a document that is numbered, dated and published, and the affected industry can see it coming. In Venezuela the equivalent announcement is often a circular that is distributed to the parties concerned and takes effect immediately, so the requirement and its notice arrive together. A manufacturer that waits for a formal amendment before adjusting a dossier will always be adjusting late, and the delay shows up as a deficiency letter rather than as a missed deadline.
Reading the hierarchy in the right order therefore matters as much as reading the right documents. The statute tells a company what the administration may require in principle; the organizational regulation tells it which unit may require it; the resolution or circular tells it what the unit currently requires in practice. A question that is answered at the third level should never be escalated to the first, and a question that is genuinely about the limits of authority should never be settled by citing a circular.
4. Practical recommendations
- Build a four-level regulatory ledger covering law, regulation, resolution and circular, and annotate each level separately with its effective date and status. Maintaining only the statutory level is the most common and most costly omission in Venezuelan projects.
- For any oral or counter-level requirement from SACS, ask for the written basis and check which level it belongs to. Where the basis is a circular, confirm that the version in hand is the current one before acting on it.
- Avoid generic compliance language such as compliance with Venezuelan law in contracts. Specify the instrument number, the article and the date, so that a change in the executing rules is visible as a change in obligation rather than as an interpretation dispute.
- Where a dispute or appeal arises, return to the principled provisions of the Organic Health Law to locate the argumentative basis, and pair that argument with the specific subordinate instrument that the administration applied.
5. Verification checklist
- □ Confirmed whether Gaceta Oficial N° 36.579 has been followed by any amending or partially revising instrument
- □ Confirmed that the full list of subordinate instruments applicable to this product has been collected, at resolution and circular level
- □ Confirmed the status of every cited instrument and removed those that are repealed or superseded
- □ Confirmed that no conflict exists between the statutory level and the circular level
- □ Recorded the date of this verification, October 29, 2026, in the internal ledger
Regulatory information verified as of October 29, 2026.
For a Venezuela market-entry feasibility assessment covering your specific product, contact the GRZAN regulatory team. GRZAN supports manufacturers, importers and authorized representatives with device registration in Venezuela: building the four-level regulatory ledger, identifying the subordinate instruments that actually govern a submission, and preparing filings that cite the correct instrument at the correct level. Reach us at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us